BNP Paribas Financial Markets
CCCC icon

BNP Paribas Financial Markets’s C4 Therapeutics CCCC Stock Holding History

BNP Paribas Financial Markets’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Sell
74,373
-115,975
-61% -$397K ﹤0.01% 3952
2026
Q1 		$501K Buy
190,348
+188,187
+8,708% +$443K ﹤0.01% 3589
2025
Q4 		$4.13K Sell
2,161
-78,645
-97% -$186K ﹤0.01% 5279
2025
Q3 		$179K Sell
80,806
-125,371
-61% -$301K ﹤0.01% 4055
2025
Q2 		$295K Buy
206,177
+188,081
+1,039% +$274K ﹤0.01% 3614
2025
Q1 		$29K Buy
18,096
+11,354
+168% +$33.9K ﹤0.01% 4441
2024
Q4 		$24.3K Buy
+6,742
New +$33.5K ﹤0.01% 4680

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets's CCCC Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its C4 Therapeutics (CCCC) stake by 61% in Q2 2026, selling an estimated $397K and leaving 74,373 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

BNP Paribas Financial Markets first reported a position in CCCC in Q4 2024 and has held it in 7 quarters since. The position peaked at $501K in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • BNP Paribas Financial Markets held 74,373 shares of C4 Therapeutics worth $347K as of Q2 2026.
  • BNP Paribas Financial Markets sold 115,975 C4 Therapeutics shares in Q2 2026, an estimated $397K.
  • C4 Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3952 holding.
  • BNP Paribas Financial Markets first reported a position in C4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's C4 Therapeutics position peaked at $501K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.